Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile InfectionBusiness Wire • 11/10/21
Seres Therapeutics to Host Third Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2021Business Wire • 11/04/21
Analysts Estimate Seres Therapeutics (MCRB) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 11/01/21
Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scientific MeetingBusiness Wire • 10/26/21
Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021Business Wire • 10/02/21
Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile InfectionBusiness Wire • 09/29/21
Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile InfectionBusiness Wire • 09/15/21
Seres Therapeutics to Present at Canaccord Genuity 41st Annual Growth ConferenceBusiness Wire • 08/05/21
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/03/21
Seres Therapeutics (MCRB) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/03/21
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business UpdatesBusiness Wire • 08/03/21
Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021Business Wire • 07/29/21
Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative ColitisBusiness Wire • 07/22/21
Seres Therapeutics Stock Plunges As Ulcerative Colitis Candidate Disappoints In Mid-Stage StudyBenzinga • 07/22/21
Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative ColitisBusiness Wire • 07/22/21
Implied Volatility Surging for Seres Therapeutics (MCRB) Stock OptionsZacks Investment Research • 07/07/21